







































Emmanuel Ifeanyi Obeagu et al.                                                                                                Asian Journal of Dental and Health Sciences. 2025; 5(2):1-7 

[1]                                                                                                                                                                                                                                              AJDHS.COM 

 

 

Available online at ajdhs.com 

Asian Journal of Dental and Health Sciences 
Open Access to Dental and Medical Research 

Copyright  © 2025 The  Author(s): This is an open-access article distributed under the terms of the CC BY-NC 4.0 
which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use provided the 

original author and source are credited  

 

 

Neurocognitive Impairment in HIV-Positive Sickle Cell Patients 

Emmanuel Ifeanyi Obeagu 1*  and Olga Geogievna Goryacheva 2 

1 Department of Biomedical and Laboratory Science, Africa University, Zimbabwe 

2 Perm State Medical University named after Academician E.A. Wagner, Russia 

Article Info: 
_____________________________________________ 
Article History: 

Received   04 Jan 2025     
Reviewed  11 Feb 2025 
Accepted   02 March 2025 
Published 15 June 2025 

_____________________________________________ 
Cite this article as:  

Obeagu EI, Goryacheva OG, Neurocognitive 
Impairment in HIV-Positive Sickle Cell 
Patients, Asian Journal of Dental and Health 
Sciences. 2025; 5(2):1-7                                                                     

DOI: http://dx.doi.org/10.22270/ajdhs.v5i2.120           

Abstract 
_________________________________________________________________________________________________________________ 

Neurocognitive impairment is a significant yet often underappreciated complication in individuals 
co-infected with human immunodeficiency virus (HIV) and sickle cell disease (SCD). This review 
explores the interplay between these two conditions, highlighting the mechanisms that contribute to 
cognitive deficits. Chronic inflammation, vascular complications, and psychosocial stressors 
associated with both HIV and SCD create a unique vulnerability to neurocognitive decline, impacting 
daily functioning and overall quality of life. The prevalence of neurocognitive impairment in this 
population is concerning, with studies indicating that individuals with SCD may experience 
increased cognitive challenges due to the compounded effects of their condition and HIV-related 
factors. This article synthesizes current research on the prevalence, risk factors, and potential 
interventions for managing neurocognitive impairment in HIV-positive sickle cell patients. By 
identifying the unique challenges faced by this population, we can develop targeted therapeutic 
strategies aimed at preserving cognitive function and enhancing the quality of life. 

Keywords: Neurocognitive Impairment, HIV, Sickle Cell Disease, Inflammation, Cognitive Function 

*Address for Correspondence:   

Emmanuel Ifeanyi Obeagu, Department of Biomedical and Laboratory Science, Africa University, Zimbabwe 

 

Introduction 

Neurocognitive impairment has emerged as a significant 
concern in the context of chronic illnesses, particularly 
among individuals living with human immunodeficiency 
virus (HIV) and sickle cell disease (SCD). Both 
conditions independently contribute to a range of 
complications, including neurological deficits; however, 
their co-occurrence presents a unique clinical challenge. 
With the advent of effective antiretroviral therapies, the 
life expectancy of HIV-positive individuals has improved 
dramatically, leading to an increasing population of 
patients facing the dual burden of HIV and SCD. This 
demographic shift necessitates a comprehensive 
understanding of the neurocognitive implications 
associated with these concurrent conditions.1-2 HIV-
associated neurocognitive disorder (HAND) 
encompasses a spectrum of cognitive impairments, from 
mild deficits to severe dementia, affecting a substantial 
proportion of HIV-infected individuals. In patients with 
SCD, neurocognitive issues can arise due to a variety of 
factors, including recurrent pain episodes, silent 
cerebral infarcts, and other vascular complications that 
compromise cerebral blood flow. The intersection of 
these two conditions complicates the clinical picture, as 
individuals may experience compounded cognitive 
challenges that significantly impact their daily 
functioning, educational attainment, and overall quality 
of life.3-4 Chronic inflammation is a key feature in both 

HIV and SCD, contributing to neurocognitive 
impairment through various mechanisms. In HIV, the 
persistent inflammatory response associated with viral 
replication can lead to neuroinflammation, disrupting 
neuronal signaling and promoting neurodegeneration. 
In patients with SCD, hemolysis and the subsequent 
release of inflammatory mediators can similarly impact 
brain health. This shared inflammatory milieu 
exacerbates cognitive decline in individuals with both 
conditions, underscoring the need for a deeper 
exploration of the interplay between inflammation and 
neurocognitive function.5-6 

Moreover, vascular complications are prevalent in both 
HIV and SCD, further increasing the risk of cognitive 
impairment. In SCD, episodes of vaso-occlusion can lead 
to ischemic damage and silent cerebral infarcts, which 
are often asymptomatic but can have long-term 
consequences for cognitive function. HIV-associated 
changes in cerebral vasculature, including inflammation 
and endothelial dysfunction, can similarly impair blood 
flow to critical brain regions. Understanding how these 
vascular changes contribute to neurocognitive decline is 
crucial for developing targeted interventions that 
address the unique needs of this population.7-8 

Psychosocial factors also play a significant role in 
neurocognitive impairment among HIV-positive sickle 
cell patients. The chronic stress associated with 
managing multiple health conditions, coupled with 

                     Open Access                                                                                                                                                                                                                Review Article                                                                           

http://jddtonline.info/
http://dx.doi.org/10.22270/ajdhs.v5i2.120
https://crossmark.crossref.org/dialog/?doi=10.22270/ajdhs.v5i2.120&amp;domain=pdf
https://orcid.org/0000-0002-4538-0161


Emmanuel Ifeanyi Obeagu et al.                                                                                                Asian Journal of Dental and Health Sciences. 2025; 5(2):1-7 

[2]                                                                                                                                                                                                                                              AJDHS.COM 

social determinants of health such as socioeconomic 
status and access to healthcare, can exacerbate cognitive 
decline. Anxiety, depression, and social isolation are 
common in this patient population, further impacting 
cognitive function and quality of life. Addressing these 
psychosocial aspects is essential for a holistic approach 
to patient care and cognitive health.9-10 Assessing 
neurocognitive function in this complex population 
requires a comprehensive approach that considers both 
clinical and contextual factors. Standardized 
neuropsychological assessments, along with qualitative 
measures such as patient-reported outcomes and 
caregiver observations, can provide valuable insights 
into cognitive functioning. Early identification of 
cognitive deficits allows for timely intervention, which 
is critical for preserving cognitive health and improving 
overall patient outcomes.11-12 

Epidemiology of Neurocognitive Impairment in 
HIV and SCD 

The epidemiology of neurocognitive impairment among 
individuals with human immunodeficiency virus (HIV) 
and sickle cell disease (SCD) is complex and 
multifactorial, with both conditions contributing to an 
increased risk of cognitive deficits. Studies have shown 
that neurocognitive impairment is prevalent in both 
populations, but the co-occurrence of HIV and SCD 
further exacerbates this issue. In HIV-positive 
individuals, it is estimated that between 30% and 50% 
exhibit some degree of cognitive dysfunction, ranging 
from mild cognitive impairment to more severe forms of 
HIV-associated neurocognitive disorder (HAND). This 
impairment can manifest as difficulties in attention, 
memory, executive function, and psychomotor speed, 
significantly affecting the individual's quality of life and 
daily functioning.13-15 Similarly, SCD is associated with 
an elevated risk of neurocognitive deficits, primarily due 
to the disease's complications, such as recurrent pain 
episodes, silent cerebral infarcts, and cerebrovascular 
accidents. Studies indicate that approximately 20% to 
30% of children and adults with SCD experience 
cognitive impairments, with a higher prevalence 
observed in those with a history of cerebrovascular 
events. Neuroimaging studies have revealed that silent 
cerebral infarcts are common in individuals with SCD, 
occurring in up to 50% of affected patients, which can 
lead to subtle yet significant cognitive declines. The 
cumulative effects of recurrent pain, hypoxia, and 
vascular occlusion further increase the risk of cognitive 
impairment in this population.16-17 

When considering the combined effects of HIV and SCD, 
the prevalence of neurocognitive impairment is even 
more pronounced. Research indicates that individuals 
co-infected with HIV and SCD experience a higher 
incidence of cognitive deficits compared to those with 
either condition alone. This heightened risk may be 
attributed to the overlapping pathophysiological 
mechanisms of both diseases, including chronic 
inflammation, oxidative stress, and vascular 
dysfunction. Additionally, the psychosocial stressors 
associated with managing two chronic conditions can 
contribute to cognitive decline, further complicating the 

epidemiological landscape.18-19 Demographic factors 
also play a significant role in the prevalence of 
neurocognitive impairment among individuals with HIV 
and SCD. Age, sex, and socioeconomic status can 
influence cognitive outcomes, with older individuals and 
those from lower socioeconomic backgrounds at greater 
risk for cognitive deficits. Furthermore, access to 
healthcare and effective treatment options can impact 
the management of both HIV and SCD, potentially 
influencing the degree of neurocognitive impairment 
observed in these populations.20 

Mechanisms of Neurocognitive Impairment in 
HIV-Positive Sickle Cell Patients 

Neurocognitive impairment in individuals co-infected 
with human immunodeficiency virus (HIV) and sickle 
cell disease (SCD) arises from a complex interplay of 
biological, neurological, and psychosocial mechanisms.  

1. Chronic Inflammation: 

Both HIV and SCD are associated with chronic 
inflammatory states that significantly contribute to 
neurocognitive impairment. In HIV, the persistence of 
viral replication leads to elevated levels of pro-
inflammatory cytokines, which can disrupt neuronal 
function and promote neuroinflammation. This 
inflammatory milieu can result in neuronal apoptosis, 
synaptic dysfunction, and altered neurotransmitter 
signaling, all of which may impair cognitive processes. 
In SCD, recurrent vaso-occlusive crises and hemolysis 
contribute to inflammation, releasing inflammatory 
mediators that can further compromise brain health. 
The combined inflammatory burden in co-infected 
patients can exacerbate cognitive deficits, leading to 
more pronounced neurocognitive impairment.21-22 

2. Vascular Dysfunction: 

Cerebrovascular complications are prevalent in both 
HIV and SCD, contributing to the risk of neurocognitive 
impairment. In SCD, episodes of vaso-occlusion can 
cause ischemic damage and silent cerebral infarcts, 
leading to subtle cognitive declines that may accumulate 
over time. Similarly, HIV-related changes in vascular 
health, including endothelial dysfunction and increased 
vascular permeability, can compromise blood flow to 
the brain. The resultant hypoxia and nutrient 
deprivation can lead to neuronal injury and cognitive 
deficits. The intersection of these vascular 
complications in co-infected patients can significantly 
impact cerebral perfusion and overall cognitive 
function.23 

3. Neuroanatomical Changes: 

Neuroimaging studies have demonstrated structural 
changes in the brains of individuals with HIV and SCD. 
In HIV-positive individuals, findings may include 
cortical atrophy, white matter lesions, and changes in 
basal ganglia structure. These changes can disrupt 
normal brain function and contribute to cognitive 
impairment. In SCD, the presence of silent cerebral 
infarcts and alterations in brain morphology has been 
observed, correlating with cognitive deficits. In co-
infected patients, these neuroanatomical alterations 



Emmanuel Ifeanyi Obeagu et al.                                                                                                Asian Journal of Dental and Health Sciences. 2025; 5(2):1-7 

[3]                                                                                                                                                                                                                                              AJDHS.COM 

may be compounded, leading to a more severe 
manifestation of cognitive impairment.24 

4. Oxidative Stress: 

Oxidative stress is another critical mechanism that 
contributes to neurocognitive impairment in this 
population. Both HIV and SCD are associated with 
increased oxidative stress due to the release of reactive 
oxygen species (ROS) from inflammatory cells and 
vascular dysfunction. Elevated levels of oxidative stress 
can lead to neuronal damage, mitochondrial 
dysfunction, and impaired synaptic plasticity. This 
oxidative burden can further exacerbate cognitive 
deficits, highlighting the need for interventions that 
target oxidative stress as a potential therapeutic 
strategy.25 

5. Psychosocial Factors: 

Psychosocial stressors significantly impact 
neurocognitive function among HIV-positive sickle cell 
patients. Chronic illness, stigma, and socioeconomic 
challenges can lead to heightened anxiety and 
depression, both of which are known to negatively affect 
cognitive performance. The interplay between mental 
health and cognitive function is particularly relevant in 
this population, as psychosocial stress can exacerbate 
the biological mechanisms contributing to 
neurocognitive impairment. Addressing these 
psychosocial factors through support systems and 
mental health interventions is essential for improving 
cognitive outcomes.26-27 

Risk Factors for Cognitive Decline in HIV-
Positive Sickle Cell Patients 

Cognitive decline in individuals co-infected with human 
immunodeficiency virus (HIV) and sickle cell disease 
(SCD) is influenced by a myriad of risk factors that can 
exacerbate neurocognitive impairment.  

1. Age: 

Age is a significant risk factor for cognitive decline in 
both HIV and SCD populations. As individuals age, the 
natural decline in cognitive function can be 
compounded by the effects of chronic illnesses. Older 
adults with HIV are at increased risk of neurocognitive 
disorders due to the cumulative impact of HIV-related 
neurotoxicity and the aging process itself. In SCD, age-
related changes in brain structure and function, coupled 
with a history of cerebrovascular events, further 
heighten the risk of cognitive impairment.28 

2. Disease Severity: 

The severity of both HIV and SCD can significantly 
influence cognitive outcomes. In HIV, factors such as 
high viral load, low CD4 counts, and advanced stages of 
disease are associated with increased risk of 
neurocognitive impairment. In SCD, individuals with a 
history of stroke, recurrent vaso-occlusive crises, and 
chronic pain are more likely to experience cognitive 
deficits. The cumulative burden of these conditions can 
exacerbate cognitive decline, making disease 
management critical in reducing risk.29 

3. Inflammation and Immune Dysfunction: 

Chronic inflammation and immune dysfunction play a 
pivotal role in cognitive decline among co-infected 
patients. Elevated levels of pro-inflammatory cytokines, 
common in both HIV and SCD, have been linked to 
neuroinflammation and neuronal damage. The 
persistent inflammatory response associated with HIV 
can lead to neurocognitive disorders, while the 
inflammatory milieu in SCD can exacerbate these effects. 
Individuals with both conditions may experience 
heightened inflammatory responses, increasing their 
risk of cognitive impairment.30 

4. Socioeconomic Status and Access to Healthcare: 

Socioeconomic factors significantly influence health 
outcomes and can exacerbate cognitive decline in HIV-
positive sickle cell patients. Lower socioeconomic status 
is associated with limited access to healthcare, which 
can affect the management of both HIV and SCD. 
Individuals facing economic hardships may experience 
higher levels of stress, less engagement in health-
promoting behaviors, and inadequate access to 
necessary medical interventions, all of which can 
contribute to cognitive decline. Additionally, education 
level may also play a role, as lower educational 
attainment is linked to poorer cognitive outcomes.31 

5. Mental Health Conditions: 

Mental health comorbidities, such as depression and 
anxiety, are prevalent among individuals with HIV and 
SCD, significantly impacting cognitive function. 
Psychological distress can exacerbate cognitive decline, 
as mental health issues can interfere with attention, 
memory, and executive functioning. In individuals co-
infected with HIV and SCD, the interplay of chronic 
illness, psychosocial stressors, and mental health 
challenges creates a compounded risk for cognitive 
impairment. Addressing mental health concerns is 
essential for holistic patient care and cognitive health 
preservation.32 

6. Lifestyle Factors: 

Lifestyle factors, including diet, physical activity, and 
substance use, can also influence cognitive outcomes in 
this population. Poor nutrition and sedentary lifestyles 
are common among individuals with chronic illnesses, 
which can exacerbate inflammation and cognitive 
decline. Substance use, particularly alcohol and 
recreational drugs, can further impair cognitive function 
and interact negatively with medications used to 
manage HIV and SCD. Promoting healthy lifestyle 
choices is crucial for mitigating cognitive decline in co-
infected patients.33 

7. History of Cerebrovascular Events: 

A history of cerebrovascular events, such as strokes or 
transient ischemic attacks (TIAs), significantly increases 
the risk of cognitive decline in both HIV and SCD 
populations. Silent cerebral infarcts are particularly 
concerning in SCD patients, often leading to undetected 
but progressive cognitive impairment. In HIV-positive 
individuals, cerebrovascular complications can result 



Emmanuel Ifeanyi Obeagu et al.                                                                                                Asian Journal of Dental and Health Sciences. 2025; 5(2):1-7 

[4]                                                                                                                                                                                                                                              AJDHS.COM 

from both the direct effects of the virus and secondary 
factors such as hypertension and hyperlipidemia. The 
presence of prior cerebrovascular events indicates a 
higher likelihood of subsequent cognitive decline.34 

Assessment of Neurocognitive Function in HIV-
Positive Sickle Cell Patients 

The assessment of neurocognitive function in 
individuals co-infected with human immunodeficiency 
virus (HIV) and sickle cell disease (SCD) is crucial for 
identifying cognitive deficits and tailoring appropriate 
interventions. Given the complexities associated with 
both conditions, a comprehensive approach that 
incorporates various assessment tools and 
methodologies is essential for accurately evaluating 
neurocognitive function. Below are key components and 
considerations in the assessment process: 

1. Clinical Evaluation: 

The initial assessment of neurocognitive function 
typically begins with a thorough clinical evaluation, 
which includes taking a detailed medical history and 
performing a physical examination. This process helps 
identify any potential neurological symptoms, 
psychiatric comorbidities, and the severity of both HIV 
and SCD. Clinicians should gather information on the 
patient's cognitive concerns, daily functioning, and any 
changes in behavior or mood, which may provide 
valuable context for understanding their cognitive 
status.35 

2. Standardized Neuropsychological Testing: 

Standardized neuropsychological tests are essential 
tools for objectively assessing cognitive function in co-
infected individuals. These tests evaluate various 
cognitive domains, including attention, memory, 
executive function, language, and visuospatial skills. 
Commonly used assessments include the Mini-Mental 
State Examination (MMSE), Montreal Cognitive 
Assessment (MoCA), and more extensive battery tests 
like the Wechsler Adult Intelligence Scale (WAIS) and 
the Wechsler Memory Scale (WMS). Administering these 
tests allows clinicians to quantify cognitive impairments 
and track changes over time, facilitating targeted 
interventions.36 

3. Functional Assessments: 

In addition to standardized testing, functional 
assessments are critical for understanding how 
cognitive deficits impact daily living activities. 
Instruments such as the Functional Independence 
Measure (FIM) and the Activities of Daily Living (ADL) 
scale evaluate an individual's ability to perform 
essential tasks, including self-care, mobility, and 
communication. Assessing functional outcomes 
provides insights into how cognitive impairments affect 
the patient’s quality of life and independence, guiding 
rehabilitation efforts.37 

4. Neuroimaging Techniques: 

Neuroimaging techniques, such as magnetic resonance 
imaging (MRI) and computed tomography (CT), play a 
valuable role in the assessment of neurocognitive 

function. These imaging modalities can identify 
structural brain changes, such as cerebral atrophy, 
white matter lesions, and silent cerebral infarcts, which 
may contribute to cognitive impairment. In patients 
with SCD, neuroimaging can help detect changes related 
to ischemic damage, while in HIV-positive individuals, it 
can reveal the effects of the virus on brain structures. 
The integration of neuroimaging findings with cognitive 
assessments can enhance the understanding of the 
underlying mechanisms of impairment.38 

5. Psychosocial and Behavioral Assessments: 

Evaluating psychosocial factors is essential in 
understanding the broader context of neurocognitive 
function in co-infected individuals. Assessing mental 
health conditions, such as depression and anxiety, can 
provide insights into how these issues may affect 
cognitive performance. Tools like the Beck Depression 
Inventory (BDI) or the Hamilton Anxiety Rating Scale 
(HAM-A) can be used to quantify the impact of 
psychosocial factors on cognitive function. Additionally, 
assessing lifestyle factors, such as substance use and 
social support, can help identify areas that require 
intervention to improve cognitive health.39 

6. Longitudinal Assessment: 

Neurocognitive function should be assessed 
longitudinally to track changes over time, particularly in 
patients with chronic illnesses like HIV and SCD. Regular 
cognitive evaluations can help identify the onset of 
cognitive decline early, allowing for timely 
interventions. Longitudinal studies can also provide 
valuable information on the natural progression of 
cognitive impairment in co-infected individuals, 
informing treatment strategies and resource 
allocation.40 

7. Multidisciplinary Approach: 

Given the complexity of neurocognitive impairment in 
HIV-positive sickle cell patients, a multidisciplinary 
approach is essential for comprehensive assessment 
and management. Collaboration among healthcare 
providers, including neurologists, psychologists, social 
workers, and primary care physicians, ensures that all 
aspects of a patient’s health are considered. This 
approach facilitates the development of personalized 
treatment plans that address both cognitive and 
psychosocial needs, ultimately improving patient 
outcomes.41 

Potential Therapeutic Approaches for 
Neurocognitive Impairment in HIV-Positive 
Sickle Cell Patients 

Addressing neurocognitive impairment in individuals 
co-infected with human immunodeficiency virus (HIV) 
and sickle cell disease (SCD) necessitates a multifaceted 
therapeutic approach. Given the complexity of both 
conditions and their impact on cognitive function, 
therapeutic strategies should aim to mitigate cognitive 
decline, manage comorbidities, and enhance overall 
quality of life. Here are several potential therapeutic 
approaches: 



Emmanuel Ifeanyi Obeagu et al.                                                                                                Asian Journal of Dental and Health Sciences. 2025; 5(2):1-7 

[5]                                                                                                                                                                                                                                              AJDHS.COM 

1. Antiretroviral Therapy (ART): 

Effective antiretroviral therapy (ART) is crucial in 
managing HIV and preventing neurocognitive 
impairment. ART reduces viral load, improves immune 
function, and decreases inflammation, all of which are 
associated with better cognitive outcomes. Ensuring 
adherence to ART is essential, as non-adherence can 
lead to viral rebound and increased risk of 
neurocognitive decline. Regular monitoring of treatment 
efficacy and side effects can help optimize ART regimens 
for co-infected individuals, contributing to improved 
cognitive health.42 

2. Hydroxyurea Therapy: 

Hydroxyurea is a cornerstone treatment for sickle cell 
disease, primarily used to reduce the frequency of vaso-
occlusive crises and associated complications. Research 
suggests that hydroxyurea may also have 
neuroprotective effects, potentially improving cognitive 
function in SCD patients. By increasing fetal hemoglobin 
levels and reducing hemolysis, hydroxyurea may 
mitigate the impact of sickle cell disease on brain health, 
thus reducing the risk of neurocognitive impairment.43 

3. Cognitive Rehabilitation Therapy: 

Cognitive rehabilitation therapy (CRT) involves 
structured interventions aimed at improving cognitive 
function and compensating for cognitive deficits. CRT 
can be tailored to the specific needs of HIV-positive SCD 
patients, focusing on areas such as attention, memory, 
and executive functioning. Techniques may include 
cognitive exercises, memory aids, and compensatory 
strategies that help individuals manage daily tasks 
despite cognitive impairments. Engaging in cognitive 
rehabilitation can enhance patients' coping skills and 
improve their overall quality of life.44 

4. Psychosocial Interventions: 

Addressing psychosocial factors is vital for managing 
neurocognitive impairment. Psychosocial interventions, 
including counseling and support groups, can help 
individuals cope with the emotional and psychological 
aspects of living with chronic illnesses. Strategies to 
reduce anxiety and depression, which are common in 
co-infected patients, can improve cognitive function and 
overall well-being. Additionally, fostering social support 
networks can provide emotional resilience, further 
aiding cognitive health.45 

5. Lifestyle Modifications: 

Encouraging healthy lifestyle modifications can play a 
significant role in preserving cognitive function. 
Interventions focusing on nutrition, physical activity, 
and sleep hygiene can help improve overall health and 
cognitive performance. A balanced diet rich in 
antioxidants, omega-3 fatty acids, and essential vitamins 
supports brain health. Regular physical activity has 
been shown to enhance cognitive function and reduce 
inflammation. Moreover, promoting good sleep hygiene 
is critical, as sleep disturbances are prevalent in both 
HIV and SCD populations and can negatively impact 
cognitive function.46 

6. Pharmacological Interventions for Cognitive 
Symptoms: 

In some cases, pharmacological interventions may be 
considered to address specific cognitive symptoms. 
Medications such as cholinesterase inhibitors or NMDA 
receptor antagonists may help improve cognitive 
function in individuals with neurocognitive disorders. 
However, careful evaluation and monitoring are 
necessary to assess the efficacy and potential side 
effects of these medications, particularly in patients 
with comorbid conditions.47 

7. Neuroprotective Agents: 

Exploring the use of neuroprotective agents could 
provide additional therapeutic avenues for mitigating 
cognitive impairment in co-infected patients. Agents 
that target inflammation, oxidative stress, and 
excitotoxicity may hold promise in preserving cognitive 
function. Research into compounds like antioxidants, 
anti-inflammatory agents, and neurotrophic factors 
could pave the way for novel treatment strategies aimed 
at protecting neuronal health in HIV-positive SCD 
patients.48 

8. Multidisciplinary Care Approach: 

Implementing a multidisciplinary care approach that 
integrates medical, psychological, and social services is 
essential for addressing the complex needs of co-
infected individuals. Collaboration among healthcare 
providers, including hematologists, infectious disease 
specialists, neurologists, psychologists, and social 
workers, ensures comprehensive care that addresses 
both physical and cognitive health. This approach can 
facilitate early identification of cognitive deficits, timely 
interventions, and coordinated management of 
comorbidities, ultimately improving patient outcomes.48 

Conclusion 

Neurocognitive impairment in individuals co-infected 
with HIV and sickle cell disease (SCD) presents a 
significant challenge, impacting their quality of life and 
overall health outcomes. The intricate interplay 
between these two conditions necessitates a 
comprehensive understanding of the mechanisms 
underlying cognitive decline and the multifactorial 
approaches required for effective management. 
Through a combination of effective antiretroviral 
therapy, sickle cell management strategies, cognitive 
rehabilitation, psychosocial support, and lifestyle 
modifications, it is possible to mitigate the effects of 
neurocognitive impairment in this population. The 
assessment and management of neurocognitive function 
in HIV-positive SCD patients should adopt a 
multidisciplinary approach, incorporating the expertise 
of various healthcare providers. This collaboration 
enables a holistic perspective on patient care, 
addressing both the physical and cognitive aspects of 
their health. Ongoing research into novel therapeutic 
interventions, neuroprotective agents, and personalized 
care strategies will be essential in advancing our 
understanding and management of cognitive 
impairment in co-infected individuals. 



Emmanuel Ifeanyi Obeagu et al.                                                                                                Asian Journal of Dental and Health Sciences. 2025; 5(2):1-7 

[6]                                                                                                                                                                                                                                              AJDHS.COM 

Conflict of Interest: Author declares no potential 

conflict of interest with respect to the contents, 

authorship, and/or publication of this article. 

Source of Support: Nil 

Funding: The authors declared that this study has 

received no financial support. 

Informed Consent Statement: Not applicable.  

Data Availability Statement: The data supporting in 

this paper are available in the cited references.  

Ethics approval: Not applicable. 

References 

1. Owusu ED, Visser BJ, Nagel IM, Mens PF, Grobusch MP. The 
interaction between sickle cell disease and HIV infection: a 
systematic review. Clinical Infectious Diseases. 2015; 60(4):612-
626. https://doi.org/10.1093/cid/ciu832 PMid:25344542 

2. Boateng LA, Ngoma AM, Bates I, Schonewille H. Red blood cell 
alloimmunization in transfused patients with sickle cell disease in 
sub-Saharan Africa; a systematic review and meta-analysis. 
Transfusion Medicine Reviews. 2019; 33(3):162-169. 
https://doi.org/10.1016/j.tmrv.2019.06.003 PMid:31345590 

3. Ola B, Olushola O, Ebenso B, Berghs M. Sickle Cell Disease and Its 
Psychosocial Burdens in Africa. InSickle Cell Disease in Sub-
Saharan Africa 2024: 67-80. Routledge. 
https://doi.org/10.4324/9781003467748-7 

4. Obeagu EI, Reducing Hospitalization Rates: The Preventive Benefits 
of Blood Transfusions in HIV Care, International Journal of 
Medical Sciences and Pharma Research, 2024;10(3):29-34 
https://doi.org/10.22270/ijmspr.v10i3.111 

5. Ochocinski D, Dalal M, Black LV, Carr S, Lew J, Sullivan K, Kissoon N. 
Life-threatening infectious complications in sickle cell disease: a 
concise narrative review. Frontiers in Pediatrics. 2020; 8:38. 
https://doi.org/10.3389/fped.2020.00038 PMid:32154192 
PMCid:PMC7044152 

6. Obeagu EI, Obeagu GU, Okwuanaso CB. Optimizing Immune Health 
in HIV Patients through Nutrition: A Review. Elite Journal of 
Immunology, 2024; 2(1): 14-33 

7. Obeagu EI, Obeagu GU. Platelet Distribution Width (PDW) as a 
Prognostic Marker for Anemia Severity in HIV Patients: A 
Comprehensive Review. Journal home page: http://www. 
journalijiar. com.;12(01). 

8. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: 
Key to Breaking the Chain of HIV Transmission. Elite Journal of 
Public Health, 2024; 2 (1): 52-61 

9. Obeagu EI, Obeagu GU. Hematocrit Fluctuations in HIV Patients Co-
infected with Malaria Parasites: A Comprehensive Review. Int. J. 
Curr. Res. Med. Sci. 2024; 10(1):25-36. 
https://doi.org/10.22270/ijmspr.v10i2.95 

10. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk 
Mitigation and Benefits for Improved Patient Outcomes. Asian J 
Dental Health Sci, 2024; 4(1):32-7. 
https://doi.org/10.22270/ajdhs.v4i1.62 

11. Obeagu EI, Obeagu GU. Advancements in HIV Prevention: Africa's 
Trailblazing Initiatives and Breakthroughs. Elite Journal of Public 
Health, 2024; 2 (1): 52-63 

12. Obeagu EI, Obeagu GU. Optimizing Blood Transfusion Protocols for 
Breast Cancer Patients Living with HIV: A Comprehensive Review. 
Elite Journal of Nursing and Health Science, 2024; 2(2):1-17 

13. Obeagu EI, Obeagu GU. Understanding ART and Platelet 
Functionality: Implications for HIV Patients. Elite Journal of HIV, 
2024; 2(2): 60-73 1 

14. Obeagu EI, Obeagu GU. Hematologic Considerations in Breast 
Cancer Patients with HIV: Insights into Blood Transfusion 
Strategies. Elite Journal of Health Science, 2024; 2(2): 20- 35 

15. Obeagu EI, Obeagu GU. Impact of Maternal Eosinophils on 
Neonatal Immunity in HIVExposed Infants: A Review. Elite Journal 
of Immunology, 2024; 2(3): 1-18 
https://doi.org/10.22270/ajdhs.v4i2.82 

16. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, 
Ngwoke AO, Emeka-Obi OR, Ugwu OP. Hematologic Support in HIV 
Patients: Blood Transfusion Strategies and Immunological 
Considerations. Newport International Journal of Biological and 
Applied Sciences (NIJBAS) 2023. 
http://hdl.handle.net/20.500.12493/14626  

17. Ntsekhe M, Baker JV. Cardiovascular disease among persons living 
with HIV: new insights into pathogenesis and clinical 
manifestations in a global context. Circulation. 2023; 147(1):83-
100. https://doi.org/10.1161/CIRCULATIONAHA.122.057443 
PMid:36576956 

18. Obare LM, Temu T, Mallal SA, Wanjalla CN. Inflammation in HIV 
and its impact on atherosclerotic cardiovascular disease. 
Circulation research. 2024; 134(11):1515-1545 
https://doi.org/10.1161/CIRCRESAHA.124.323891 
PMid:38781301 PMCid:PMC11122788 

19. Hmiel L, Zhang S, Obare LM, Santana MA, Wanjalla CN, Titanji BK, 
Hileman CO, Bagchi S. Inflammatory and immune mechanisms for 
atherosclerotic cardiovascular disease in HIV. International 
journal of molecular sciences. 2024; 25(13):7266.  
https://doi.org/10.3390/ijms25137266 PMid:39000373 
PMCid:PMC11242562 

20. Obeagu EI, Obeagu GU. Platelet Aberrations in HIV Patients: 
Assessing Impacts of ART. Elite Journal of Haematology, 2024; 
2(3): 10-24 

21. Obeagu EI, Obeagu GU. Harnessing B Cell Responses for 
Personalized Approaches in HIV Management. Elite Journal of 
Immunology, 2024; 2(2): 15-28 

22. Belisário AR, Blatyta PF, Vivanco D, Oliveira CD, Carneiro-Proietti 
AB, Sabino EC, de Almeida-Neto C, Loureiro P, Máximo C, de 
Oliveira Garcia Mateos S, Flor-Park MV. Association of HIV 
infection with clinical and laboratory characteristics of sickle cell 
disease. BMC Infectious Diseases. 2020; 20(1):638. 
https://doi.org/10.1186/s12879-020-05366-z PMid:32854639 
PMCid:PMC7457248 

23. Obeagu EI, Addressing Sleep Disturbances: Blood Transfusions and 
Improved Sleep Patterns in HIV Patients, International Journal of 
Medical Sciences and Pharma Research, 2024;10(3):43-48 
https://doi.org/10.22270/ijmspr.v10i3.113 

24. Gill AF, Ahsan MH, Lackner AA, Veazey RS. Hematologic 
abnormalities associated with simian immunodeficieny virus 
(SIV) infection mimic those in HIV infection. Journal of Medical 
Primatology. 2012; 41(3):214-224. 
https://doi.org/10.1111/j.1600-0684.2012.00543.x 
PMid:22620272 PMCid:PMC3367385 

25. Nouraie M, Nekhai S, Gordeuk VR. Sickle cell disease is associated 
with decreased HIV but higher HBV and HCV comorbidities in US 
hospital discharge records: a cross-sectional study. Sexually 
transmitted infections. 2012; 88(7):528-533. 
https://doi.org/10.1136/sextrans-2011-050459 PMid:22628662 
PMCid:PMC3456988 

26. Obeagu EI, Obeagu GU. Hematological Changes Following Blood 
Transfusion in Young Children with Severe Malaria and HIV: A 
Critical Review. Elite Journal of Laboratory Medicine. 2024; 
2(1):33-45. 

27. Obeagu EI, Obeagu GU. The Role of L-selectin in Tuberculosis and 
HIV Coinfection: Implications for Disease Diagnosis and 
Management. Elite Journal of Public Health, 2024; 2 (1): 35-51 

28. Obeagu EI, Obeagu GU. Unraveling the Role of Eosinophil 
Extracellular Traps (EETs) in HIV-Infected Pregnant Women: A 
Review. Elite Journal of Nursing and Health Science, 2024; 2(3): 
84-99 

https://doi.org/10.1093/cid/ciu832
https://doi.org/10.1016/j.tmrv.2019.06.003
https://doi.org/10.4324/9781003467748-7
https://doi.org/10.22270/ijmspr.v10i3.111
https://doi.org/10.3389/fped.2020.00038
https://doi.org/10.22270/ijmspr.v10i2.95
https://doi.org/10.22270/ajdhs.v4i1.62
https://doi.org/10.22270/ajdhs.v4i2.82
http://hdl.handle.net/20.500.12493/14626
https://doi.org/10.1161/CIRCULATIONAHA.122.057443
https://doi.org/10.1161/CIRCRESAHA.124.323891
https://doi.org/10.3390/ijms25137266
https://doi.org/10.1186/s12879-020-05366-z
https://doi.org/10.22270/ijmspr.v10i3.113
https://doi.org/10.1111/j.1600-0684.2012.00543.x
https://doi.org/10.1136/sextrans-2011-050459


Emmanuel Ifeanyi Obeagu et al.                                                                                                Asian Journal of Dental and Health Sciences. 2025; 5(2):1-7 

[7]                                                                                                                                                                                                                                              AJDHS.COM 

29. Obeagu EI, Obeagu GU. Unveiling the Role of Innate Immune 
Activation in Pediatric HIV: A Review. Elite Journal of 
Immunology, 2024; 2(3): 33-44 

30. Obeagu EI, Obeagu, GU. Impact of Blood Transfusion on Viral Load 
Dynamics in HIVPositive Neonates with Severe Malaria: A Review. 
Elite Journal of Scientific Research and Review, 2024; 2(1): 42-60 

31. Obeagu EI, Youth-Friendly HIV Prevention: Tailoring Interventions 
for Young Populations, International Journal of Medical Sciences 
and Pharma Research, 2024;10(4):62-67. 
https://doi.org/10.22270/ijmspr.v10i4.125 

32. Obeagu EI, Faith-based initiatives, HIV awareness, religious 
communities, health education, stigma reduction, International 
Journal of Medical Sciences and Pharma Research, 2024;10(4):74-
79 https://doi.org/10.22270/ijmspr.v10i4.127 

33. Obeagu EI, Obeagu GU. P-Selectin Expression in HIV-Associated 
Coagulopathy: Implications for Treatment. Elite Journal of 
Haematology, 2024; 2(3): 25-41 

34. Obeagu EI, Obeagu GU. P-Selectin and Immune Activation in HIV: 
Clinical Implications. Elite Journal of Health Science, 2024; 2(2): 
16-29 

35. Obeagu EI, Amaeze AA, Ogbu ISI, Obeagu GU. B Cell Deficiency and 
Implications in HIV Pathogenesis: Unraveling the Complex 
Interplay. Elite Journal of Nursing and Health Science, 2024; 2(2): 
33-46 

36. Obeagu EI, Obeagu, GU. Platelet Dysfunction in HIV Patients: 
Assessing ART Risks. Elite Journal of Scientific Research and 
Review, 2024; 2(1): 1-16 

37. Kibaru EG, Nduati R, Wamalwa D, Kariuki N. Impact of highly 
active antiretroviral therapy on hematological indices among HIV-
1 infected children at Kenyatta National Hospital-Kenya: 
retrospective study. AIDS research and therapy. 2015; 12:1-8. 
https://doi.org/10.1186/s12981-015-0069-4 PMid:26279668 
PMCid:PMC4537535 

38. Enawgaw B, Alem M, Addis Z, Melku M. Determination of 
hematological and immunological parameters among HIV positive 
patients taking highly active antiretroviral treatment and 
treatment naïve in the antiretroviral therapy clinic of Gondar 
University Hospital, Gondar, Northwest Ethiopia: a comparative 
cross-sectional study. BMC hematology. 2014; 14:1-7. 
https://doi.org/10.1186/2052-1839-14-8 PMid:24666771 
PMCid:PMC3994311 

39. Gudina A, Wordofa M, Urgessa F. Immuno-hematological 
parameters among adult HIV patients before and after initiation of 

Dolutegravir based antiretroviral therapy, Addis Ababa, Ethiopia. 
Plos one. 2024; 19(10):e0310239. 
https://doi.org/10.1371/journal.pone.0310239 PMid:39480901 
PMCid:PMC11527299 

40. Geletaw T, Tadesse MZ, Demisse AG. Hematologic abnormalities 
and associated factors among HIV infected children pre-and post-
antiretroviral treatment, North West Ethiopia. Journal of blood 
medicine. 2017:99-105. https://doi.org/10.2147/JBM.S137067 
PMid:28831276 PMCid:PMC5552149 

41. Jegede FE, Oyeyi TI, Abdulrahman SA, Mbah HA, Badru T, 
Agbakwuru C, Adedokun O. Effect of HIV and malaria parasites co-
infection on immune-hematological profiles among patients 
attending anti-retroviral treatment (ART) clinic in Infectious 
Disease Hospital Kano, Nigeria. PLoS One. 2017; 12(3):e0174233. 
https://doi.org/10.1371/journal.pone.0174233 PMid:28346490 
PMCid:PMC5367709 

42. Obeagu EI, Obeagu GU. ART and Platelet Dynamics: Assessing 
Implications for HIV Patient Care. Elite Journal of Haematology. 
2024; 2(4):68-85. 

43. Obeagu EI, Ayogu EE, Obeagu GU. Impact on Viral Load Dynamics: 
Understanding the Interplay between Blood Transfusion and 
Antiretroviral Therapy in HIV Management. Elite Journal of 
Nursing and Health Science. 2024;2(2):5-15. 

44. Ciccacci F, Lucaroni F, Latagliata R, Morciano L, Mondlane E, 
Balama M, Tembo D, Gondwe J, Orlando S, Palombi L, Marazzi MC. 
Hematologic alterations and early mortality in a cohort of HIV 
positive African patients. PLoS One. 2020; 15(11):e0242068. 
https://doi.org/10.1371/journal.pone.0242068 PMid:33170905 
PMCid:PMC7654783 

45. Ashenafi G, Tibebu M, Tilahun D, Tsegaye A. Immunohematological 
Outcome Among Adult HIV Patients Taking Highly Active 
Antiretroviral Therapy for at Least Six Months in Yabelo Hospital, 
Borana, Ethiopia. Journal of Blood Medicine. 2023:543-554. 
https://doi.org/10.2147/JBM.S419414 PMid:37881654 
PMCid:PMC10595970 

46. Obeagu EI, Goryacheva OG. The Role of Inflammation in HIV and 
Sickle Cell Disease Co-Morbidity. Lifeline HIV, 2025; 3(1): 1-12 

47. Obeagu EI, Goryacheva OG. Oxidative Stress in HIV and Sickle Cell 
Disease: A Double Burden. Lifeline HIV, 2025; 3(1): 13-24 

48. Obeagu EI, Goryacheva OG. HIV and Sickle Cell Disease: A Focus on 
Liver Dysfunction. Lifeline HIV, 2025; 3(1): 25-40 

 

 

 

https://doi.org/10.22270/ijmspr.v10i4.125
https://doi.org/10.22270/ijmspr.v10i4.127
https://doi.org/10.1186/s12981-015-0069-4
https://doi.org/10.1186/2052-1839-14-8
https://doi.org/10.1371/journal.pone.0310239
https://doi.org/10.2147/JBM.S137067
https://doi.org/10.1371/journal.pone.0174233
https://doi.org/10.1371/journal.pone.0242068
https://doi.org/10.2147/JBM.S419414

